Search Results - "TRAVERSE, Jay"

Use of Pressure-Controlled Intermittent Coronary Sinus Occlusion in STEMI: The Road Not Taken by Traverse, Jay H

Get full text

When should patients with acute myocardial infarction undergo CABG? A question much in need of a randomized clinical trial? by Traverse, Jay H.

Get full text

The coronary sinus reducer – Where modern technology meets old school physiology by Traverse, Jay H.

Get full text

G-CSF’s Last Stand in STEMI by Traverse, Jay H

Get full text

Beet It by Traverse, Jay H

Get full text

Left ventricular thrombus following ST-Elevation myocardial infarction: Insights from “little” and “big” data by Traverse, Jay H.

Get full text

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial Infarction by Hare, Joshua M., MD, Traverse, Jay H., MD, Henry, Timothy D., MD, Dib, Nabil, MD, Strumpf, Robert K., MD, Schulman, Steven P., MD, Gerstenblith, Gary, MD, DeMaria, Anthony N., MD, Denktas, Ali E., MD, Gammon, Roger S., MD, Hermiller, James B., MD, Reisman, Mark A., MD, Schaer, Gary L., MD, Sherman, Warren, MD

“…Objectives Our aim was to investigate the safety and efficacy of intravenous allogeneic human mesenchymal stem cells (hMSCs) in patients with myocardial…”
Get full text

First-in-Man Study of a Cardiac Extracellular Matrix Hydrogel in Early and Late Myocardial Infarction Patients by Traverse, Jay H., MD, Henry, Timothy D., MD, Dib, Nabil, MD, Patel, Amit N., MD, Pepine, Carl, Schaer, Gary L., MD, DeQuach, Jessica A., PhD, Kinsey, Adam M., PhD, Chamberlin, Paul, MD, Christman, Karen L., PhD

“…Visual Abstract…”
Get full text

Is There a Role for Intravenous Stem Cell Delivery in Nonischemic Cardiomyopathy? by Traverse, Jay H

Get full text

Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial by Makkar, Raj R, Kereiakes, Dean J, Aguirre, Frank, Kowalchuk, Glenn, Chakravarty, Tarun, Malliaras, Konstantinos, Francis, Gary S, Povsic, Thomas J, Schatz, Richard, Traverse, Jay H, Pogoda, Janice M, Smith, Rachel R, Marbán, Linda, Ascheim, Deborah D, Ostovaneh, Mohammad R, Lima, João A C, DeMaria, Anthony, Marbán, Eduardo, Henry, Timothy D

“…Abstract Aims Cardiosphere-derived cells (CDCs) are cardiac progenitor cells that exhibit disease-modifying bioactivity in various models of cardiomyopathy and…”
Get full text

The Misguided Regulation of Cardiac Emergencies: The Rise of the IRB-Industrial Complex and the Increasing Risk to Cardiovascular Research and Our Patients by Traverse, Jay H

“…The increasing regulatory burden and cost of doing clinical trials in cardiac emergencies has greatly impacted the development of novel therapies resulting in…”
Get full text

A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure by Perin, Emerson C, Borow, Kenneth M, Silva, Guilherme V, DeMaria, Anthony N, Marroquin, Oscar C, Huang, Paul P, Traverse, Jay H, Krum, Henry, Skerrett, Donna, Zheng, Yi, Willerson, James T, Itescu, Silviu, Henry, Timothy D

“…RATIONALE:Allogeneic mesenchymal precursor cells (MPCs) have been effective in large animal models of ischemic and nonischemic heart failure (HF). OBJECTIVE:To…”
Get full text

Intramyocardial, Autologous CD34+ Cell Therapy for Refractory Angina by Losordo, Douglas W, Henry, Timothy D, Davidson, Charles, Sup Lee, Joon, Costa, Marco A, Bass, Theodore, Mendelsohn, Farrell, Fortuin, F David, Pepine, Carl J, Traverse, Jay H, Amrani, David, Ewenstein, Bruce M, Riedel, Norbert, Story, Kenneth, Barker, Kerry, Povsic, Thomas J, Harrington, Robert A, Schatz, Richard A

“…RATIONALE:A growing number of patients with coronary disease have refractory angina. Preclinical and early-phase clinical data suggest that intramyocardial…”
Get full text

Microvascular obstruction identifies a subgroup of patients who benefit from stem cell therapy following ST-elevation myocardial infarction by Davidson, Sarah J., Roncalli, Jerome, Surder, Daniel, Corti, Roberto, Chugh, Atul R., Yang, Phillip C., Henry, Timothy D., Stanberry, Larissa, Lemarchand, Patricia, Beregi, Jeau-Paul, Traverse, Jay H.

“…Microvascular obstruction (MVO) is associated with greater infarct size, adverse left-ventricular (LV) remodeling and reduced ejection fraction following…”
Get full text

Circadian Dependence of Infarct Size and Left Ventricular Function After ST Elevation Myocardial Infarction by Reiter, Ronald, Swingen, Cory, Moore, Luke, Henry, Timothy D, Traverse, Jay H

“…RATIONALE:In rodents, infarct size after ischemia/reperfusion exhibits a circadian dependence on the time of coronary occlusion. It is not known if a similar…”
Get full text

Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit+ Cardiac Stem Cells As Regenerative Therapy for Heart Failure) by Bolli, Roberto, Hare, Joshua M, March, Keith L, Pepine, Carl J, Willerson, James T, Perin, Emerson C, Yang, Phillip C, Henry, Timothy D, Traverse, Jay H, Mitrani, Raul D, Khan, Aisha, Hernandez-Schulman, Ivonne, Taylor, Doris A, DiFede, Darcy L, Lima, João A.C, Chugh, Atul, Loughran, John, Vojvodic, Rachel W, Sayre, Shelly L, Bettencourt, Judy, Cohen, Michelle, Moyé, Lem, Ebert, Ray F, Simari, Robert D

“…RATIONALE:Autologous bone marrow mesenchymal stem cells (MSCs) and c-kit cardiac progenitor cells (CPCs) are 2 promising cell types being evaluated for…”
Get full text

Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials by Henry, Timothy D, Losordo, Douglas W, Traverse, Jay H, Schatz, Richard A, Jolicoeur, E Marc, Schaer, Gary L, Clare, Robert, Chiswell, Karen, White, Christopher J, Fortuin, F David, Kereiakes, Dean J, Zeiher, Andreas M, Sherman, Warren, Hunt, Andrea S, Povsic, Thomas J

“…Abstract Aims Autologous CD34+ (auto-CD34+) cells represent an attractive option for the treatment of refractory angina. Three double-blinded randomized trials…”
Get full text

A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF trial by Bolli, Roberto, Mitrani, Raul D., Hare, Joshua M., Pepine, Carl J., Perin, Emerson C., Willerson, James T., Traverse, Jay H., Henry, Timothy D., Yang, Phillip C., Murphy, Michael P., March, Keith L., Schulman, Ivonne H., Ikram, Sohail, Lee, David P., O'Brien, Connor, Lima, Joao A., Ostovaneh, Mohammad R., Ambale‐Venkatesh, Bharath, Lewis, Gregory, Khan, Aisha, Bacallao, Ketty, Valasaki, Krystalenia, Longsomboon, Bangon, Gee, Adrian P., Richman, Sara, Taylor, Doris A., Lai, Dejian, Sayre, Shelly L., Bettencourt, Judy, Vojvodic, Rachel W., Cohen, Michelle L., Simpson, Lara, Aguilar, David, Loghin, Catalin, Moyé, Lem, Ebert, Ray F., Davis, Barry R., Simari, Robert D.

“…Aims CONCERT‐HF is an NHLBI‐sponsored, double‐blind, placebo‐controlled, Phase II trial designed to determine whether treatment with autologous bone…”
Get full text

Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction by Rao, Sunil V., MD, Zeymer, Uwe, MD, Douglas, Pamela S., MD, Al-Khalidi, Hussein, PhD, White, Jennifer A., MS, Liu, Jingyu, PhD, Levy, Howard, MD, PhD, Guetta, Victor, MD, Gibson, C. Michael, MD, Tanguay, Jean-Francois, MD, Vermeersch, Paul, MD, Roncalli, Jérôme, MD, PhD, Kasprzak, Jaroslaw D., MD, Henry, Timothy D., MD, Frey, Norbert, MD, Kracoff, Oscar, MD, Traverse, Jay H., MD, Chew, Derek P., MBBS, Lopez-Sendon, Jose, MD, Heyrman, Reinilde, MD, Krucoff, Mitchell W., MD

“…Abstract Background Bioabsorbable cardiac matrix (BCM) is a novel device that attenuates adverse left ventricular (LV) remodeling after large myocardial…”
Get full text

Of Mice and Men: The Quest to Determine a Circadian Basis for Myocardial Protection in Ischemia/Reperfusion Injury by Traverse, Jay H

Get full text